The full name of CAR-T therapy is Chimeric Antigen Receptor (CAR) T-cell Therapy. The concept originated in 1989, and achieved its first clinical success in 2012 by curing a 7-year-old child with acute lymphoblastic leukemia. CAR-T therapy is currently one of the hottest and fastest-growing fields in the biopharmaceutical industry. Innovation and R&D activities are advancing rapidly. It has not only become a new hope for curing multiple types of cancer, but also holds tremendous potential for applications in autoimmune diseases, inflammatory disorders, degenerative diseases, and organ regeneration. The field is full of opportunities and vast space for innovation and entrepreneurship.